Acadia Pharmaceuticals (ACAD) Income from Continuing Operations (2010 - 2026)

Acadia Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 3700000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 80.53% year-over-year to 3700000.0; the TTM figure through Mar 2026 stood at 375687000.0 (up 64.12% YoY), while the FY2025 annual figure was 391000000.0, up 72.66% from the prior year.
• Income from Continuing Operations was 3700000.0 for Q1 2026 at Acadia Pharmaceuticals, down from 273553000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 273553000.0 in Q4 2025 to a low of 113056000.0 in Q1 2022.
• Historically, Income from Continuing Operations has averaged 20237058.82 across 5 years, with a median of 16553000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations slumped 139.74% in 2023, then surged 2822.13% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 41675000.0 in 2022, then surged by 209.8% to 45758000.0 in 2023, then jumped by 214.15% to 143751000.0 in 2024, then jumped by 90.3% to 273553000.0 in 2025, then plunged by 98.65% to 3700000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 3700000.0 (Q1 2026), 273553000.0 (Q4 2025), and 71779000.0 (Q3 2025), per Business Quant data.